PMS2 monoallelic mutation carriers: The known unknown

McKinsey L. Goodenberger, Brittany C. Thomas, Douglas Riegert-Johnson, C. Richard Boland, Sharon E. Plon, Mark Clendenning, Aung Ko Win, Leigha Senter, Steven M. Lipkin, Zsofia K. Stadler, Finlay A. Macrae, Henry T. Lynch, Jeffrey N. Weitzel, Albert De La Chapelle, Sapna Syngal, Patrick Lynch, Susan Parry, Mark A. Jenkins, Steven Gallinger, Spring HolterMelyssa Aronson, Polly A. Newcomb, Terrilea Burnett, Loïc Le Marchand, Pavel Pichurin, Heather Hampel, Jonathan P. Terdiman, Karen H. Lu, Stephen N Thibodeau, Noralane Morey Lindor

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalGenetics in Medicine
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Guidelines
Penetrance
Germ-Line Mutation
Mutation
DNA Mismatch Repair
Colorectal Neoplasms
Neoplasms
Hereditary Nonpolyposis Colorectal Neoplasms
Early Detection of Cancer
Age of Onset
Genes
Registries
Colon
Research

Keywords

  • Lynch screening
  • Lynch syndrome
  • mismatch repair
  • PMS2
  • PMS2 monoallelic

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Goodenberger, M. L., Thomas, B. C., Riegert-Johnson, D., Boland, C. R., Plon, S. E., Clendenning, M., ... Lindor, N. M. (2016). PMS2 monoallelic mutation carriers: The known unknown. Genetics in Medicine, 18(1), 13-19. https://doi.org/10.1038/gim.2015.27

PMS2 monoallelic mutation carriers : The known unknown. / Goodenberger, McKinsey L.; Thomas, Brittany C.; Riegert-Johnson, Douglas; Boland, C. Richard; Plon, Sharon E.; Clendenning, Mark; Win, Aung Ko; Senter, Leigha; Lipkin, Steven M.; Stadler, Zsofia K.; Macrae, Finlay A.; Lynch, Henry T.; Weitzel, Jeffrey N.; De La Chapelle, Albert; Syngal, Sapna; Lynch, Patrick; Parry, Susan; Jenkins, Mark A.; Gallinger, Steven; Holter, Spring; Aronson, Melyssa; Newcomb, Polly A.; Burnett, Terrilea; Le Marchand, Loïc; Pichurin, Pavel; Hampel, Heather; Terdiman, Jonathan P.; Lu, Karen H.; Thibodeau, Stephen N; Lindor, Noralane Morey.

In: Genetics in Medicine, Vol. 18, No. 1, 01.01.2016, p. 13-19.

Research output: Contribution to journalArticle

Goodenberger, ML, Thomas, BC, Riegert-Johnson, D, Boland, CR, Plon, SE, Clendenning, M, Win, AK, Senter, L, Lipkin, SM, Stadler, ZK, Macrae, FA, Lynch, HT, Weitzel, JN, De La Chapelle, A, Syngal, S, Lynch, P, Parry, S, Jenkins, MA, Gallinger, S, Holter, S, Aronson, M, Newcomb, PA, Burnett, T, Le Marchand, L, Pichurin, P, Hampel, H, Terdiman, JP, Lu, KH, Thibodeau, SN & Lindor, NM 2016, 'PMS2 monoallelic mutation carriers: The known unknown', Genetics in Medicine, vol. 18, no. 1, pp. 13-19. https://doi.org/10.1038/gim.2015.27
Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M et al. PMS2 monoallelic mutation carriers: The known unknown. Genetics in Medicine. 2016 Jan 1;18(1):13-19. https://doi.org/10.1038/gim.2015.27
Goodenberger, McKinsey L. ; Thomas, Brittany C. ; Riegert-Johnson, Douglas ; Boland, C. Richard ; Plon, Sharon E. ; Clendenning, Mark ; Win, Aung Ko ; Senter, Leigha ; Lipkin, Steven M. ; Stadler, Zsofia K. ; Macrae, Finlay A. ; Lynch, Henry T. ; Weitzel, Jeffrey N. ; De La Chapelle, Albert ; Syngal, Sapna ; Lynch, Patrick ; Parry, Susan ; Jenkins, Mark A. ; Gallinger, Steven ; Holter, Spring ; Aronson, Melyssa ; Newcomb, Polly A. ; Burnett, Terrilea ; Le Marchand, Loïc ; Pichurin, Pavel ; Hampel, Heather ; Terdiman, Jonathan P. ; Lu, Karen H. ; Thibodeau, Stephen N ; Lindor, Noralane Morey. / PMS2 monoallelic mutation carriers : The known unknown. In: Genetics in Medicine. 2016 ; Vol. 18, No. 1. pp. 13-19.
@article{baecde7998fb46d1804e4b560d4179c0,
title = "PMS2 monoallelic mutation carriers: The known unknown",
abstract = "Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8{\%} of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.",
keywords = "Lynch screening, Lynch syndrome, mismatch repair, PMS2, PMS2 monoallelic",
author = "Goodenberger, {McKinsey L.} and Thomas, {Brittany C.} and Douglas Riegert-Johnson and Boland, {C. Richard} and Plon, {Sharon E.} and Mark Clendenning and Win, {Aung Ko} and Leigha Senter and Lipkin, {Steven M.} and Stadler, {Zsofia K.} and Macrae, {Finlay A.} and Lynch, {Henry T.} and Weitzel, {Jeffrey N.} and {De La Chapelle}, Albert and Sapna Syngal and Patrick Lynch and Susan Parry and Jenkins, {Mark A.} and Steven Gallinger and Spring Holter and Melyssa Aronson and Newcomb, {Polly A.} and Terrilea Burnett and {Le Marchand}, Lo{\"i}c and Pavel Pichurin and Heather Hampel and Terdiman, {Jonathan P.} and Lu, {Karen H.} and Thibodeau, {Stephen N} and Lindor, {Noralane Morey}",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/gim.2015.27",
language = "English (US)",
volume = "18",
pages = "13--19",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - PMS2 monoallelic mutation carriers

T2 - The known unknown

AU - Goodenberger, McKinsey L.

AU - Thomas, Brittany C.

AU - Riegert-Johnson, Douglas

AU - Boland, C. Richard

AU - Plon, Sharon E.

AU - Clendenning, Mark

AU - Win, Aung Ko

AU - Senter, Leigha

AU - Lipkin, Steven M.

AU - Stadler, Zsofia K.

AU - Macrae, Finlay A.

AU - Lynch, Henry T.

AU - Weitzel, Jeffrey N.

AU - De La Chapelle, Albert

AU - Syngal, Sapna

AU - Lynch, Patrick

AU - Parry, Susan

AU - Jenkins, Mark A.

AU - Gallinger, Steven

AU - Holter, Spring

AU - Aronson, Melyssa

AU - Newcomb, Polly A.

AU - Burnett, Terrilea

AU - Le Marchand, Loïc

AU - Pichurin, Pavel

AU - Hampel, Heather

AU - Terdiman, Jonathan P.

AU - Lu, Karen H.

AU - Thibodeau, Stephen N

AU - Lindor, Noralane Morey

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.

AB - Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.

KW - Lynch screening

KW - Lynch syndrome

KW - mismatch repair

KW - PMS2

KW - PMS2 monoallelic

UR - http://www.scopus.com/inward/record.url?scp=84954326744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954326744&partnerID=8YFLogxK

U2 - 10.1038/gim.2015.27

DO - 10.1038/gim.2015.27

M3 - Article

C2 - 25856668

AN - SCOPUS:84954326744

VL - 18

SP - 13

EP - 19

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 1

ER -